Breztri fda approval?

Yes. Breztri Aerosphere (budesonide/glycopyrronium/formoterol) is FDA-approved for COPD.

- When: FDA approved in July 2020.
- Indication: Maintenance treatment of COPD in adults (for patients not adequately treated with a single therapy or dual therapy).
- How it’s used: Inhaled via a pressurized aerosol. The usual regimen is two inhalations twice daily (morning and evening). Each inhalation delivers budesonide 320 mcg, glycopyrronium 18 mcg, and formoterol fumarate 9.6 mcg.
- Important safety notes:
- Not for asthma or for acute respiratory symptoms; not a rescue inhaler.
- Possible side effects include pneumonia, oral candidiasis (thrush), and other ICS-associated risks; may affect heart rate/blood pressure in some people.
- Use with caution in people with certain infections, glaucoma, or severe heart conditions; check for interactions with other COPD meds.
- Where to find exact labeling: If you want the official prescribing information or patient leaflet, I can summarize or point you to the FDA label.

If you’re considering this for yourself or someone else, it’s best to discuss with a clinician to ensure it’s appropriate and to get dosing tailored to the individual.